R&D efforts are focused on developing
vaccines that will meet the specific needs of different segments of the global
population (e.g. development of the Meningococcal A Vaccine in collaboration
with WHO and PATH for sub-Saharan Africa, development of Pandemic Influenza
Vaccine) as well as on improving methods of vaccine delivery for its present
range of vaccines viz. use of jet injectors, aerosol delivery, dry powder
inhalation delivery etc. An example is the development of Aerosol Measles Vaccine
which allows respiratory delivery of currently licensed Measles Vaccine, to
make it a vaccine that is more safe, immunogenic, inexpensive, needle-free and
easier to administer than an injection.
R&D initiatives also include development of better adjuvants, heat stable
vaccines, conjugate vaccines, monoclonal antibodies and others. Besides, there
is an extensive range of vaccines in the development pipeline undergoing
various stages of testing and clinical evaluation.
Recognizing the global need of immunization for cost-effective vaccines
against various infectious diseases, Serum Institute is actively associated
with international agencies like WHO, PATH, NIBSC/HPA, Bill & Melinda Gates
Foundation, CBER, AktivDry/Colorado University, EDQM, RIVM/NVI, NIH/CDC, Rhein
Biotech, USAID, University of Massachusetts and several other international
organizations. Serum Institute values the ethical principle to replace, reduce
or refine animal testing and hence is actively involved in an effort to reduce
animal suffering, and the development of possible alternatives to in vivo
testing of its products.
Serum Institute has a team of highly qualified and motivated professionals
consisting of scientists, pharmacists, chemists, microbiologists,
immunologists along with a group of medical doctors, national and
international consultants which form its core R&D group.
Serum Institute performs high quality pre-clinical and clinical research in
compliance with GLP and GCP guidelines on all its products before they are
marketed worldwide. After licensure, a diligent pharmacovigilance is
maintained as per international norms.